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pentine and isoniazid. once weekly for 3 months, provides highly 
effective chenioprophylaxis. 
Other agents: Information about in i'itro and to a lesser extent irr 
tivo activities of two oxazolidinonc compounds (U-I 00592 and U- 
1 Oll7of)) and .I nitroimidaeole conipound (PA-8.24) suggest a possiblc. 
future role for one or more of these agents. 
In conclucion, development of effective new antimycobacterial 
agents has I~ggcd f.ir behind the need for thein. lnipruved public- 
priwte sector collaboration is needed to remedy the deficiency. 
Clinical implications of antibiotics resistance 
in developing countries 
151261 Use and misuse of antibiotic policies to control 
drug resistance 
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The use ofantibiotics has led to the emergence o f a  variety ofresistant 
bacteria which have cleai-ly added to the challenge of controlling 
infections with new agents. 
Misuse of antibiotics is responsible for a general pool of resistant 
\train< in the population where there is unrestricted sale of antibiotics, 
i.e. over the counter. 
Appropriate use of antibiotic policies to control drug resistance 
should be encouraged and implemented. In order to do so, an 
.intibiotic conunittee should be responsible for tlie formulation and 
supervision of nn antibiotic pohcy.The policy will improve patient 
care hy considrred iise of antibiotics for prophylaxis and therapy, 
make hettcr use of finance, retdrd the eiiiei-gence of multiplc 
antibiotic-re\irtait bacteria and improve education of junior doctor5 
by providing guidelines for appropriate therapy. 
The antibiotic committee will have to make rational choices 
among cquiv.ilent antibiotics and classes of drugs in order to sclcct 
the least expensive. most effective 3gents.Cost should determine tlie 
telec~ion when niicrobiological, pharniacologic and other relevant 
propertics are similar. 
Data on antibiotic susceptibility of bacterial isolates from the local 
area will assist the coninlittee in producing etfective guidance for the 
patient population.The 1abor.itory should give data on  the extent of 
resistance to a particular antibiotic. When n o  local microbiology 
I h m t o r y  exicts, the ~ntibiotic policy should be based upon a baric 
formulary; when resources for i i i i c rob io lo~~  are scarce, priority 
should be given to examination of samples from nosocominl lifc- 
threatening cases. 
Inappropri'ite use o f  antibiotic policies ha5 limited the choice of 
antibiotics, and there 19 a need for iiiore prudent use ofmtibiotics in 
the treatinent ofinfections, c\pecially ui developiiig countries. 
The clinical relevance of antibiotic resistance 
for the management of pneumonia in 
developing countries 
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There is now widejpread in vitru resistance to the coninion d r u g  
used for the management of pneumonia in developing countries. 
Data from both developed and developing countries, however, show 
that iiiore than 99% of pneuniococcl identified as penicillin resistant 
in the laboratory can be treated by adequate intravenous doses of 
penicillin or .urnpicillin. Trimethoprim-sulfaiiiethoxJzolr I \  leu active 
than mioxycillin for the nianagenient of scvcre pneumonia 
in  developing countries, The lesser activity of 
trimethoprini-sulfanietho~azole wac not directly related t o  level\  of 
antimicrobial resistance to that agent, suggectiq tli'it anioxvc.illin I \  
intrinsically more active against the coninion bacteri,il agent\ cau\ing 
pneumonia. Macrolide revstance has emerged as a major problem in  
Asia, with 8O'IB of pneuniococci isolated from children in China  
exhibiting re\istance to this class of agent. Guideline\ h r  the 
manageincnt of pneuinonia reiommLmd th'it tlie breakpoints for 
penicillin resistance should be increased, so that clinicians are not 
faced with dilemma of treating 'resistmt' strains with peiiicilhii. 
Nasopharyngeal screening programs give data on mtimicrubi.il 
resistance that are comparable to those obt'iined koni sterile-\itc 
speciniens. More data are required on the impact of penicillin 
resistance on the oral management of pnrunioni.~. (:iirrent dau  
would suggest that, where affordable, ordl amoxycillin \hould replaw 
crimethoprim-siilf~iiiethoxazole as the drug of choice fix the 
management of moderate to severe pncuniococc,~l piiciniioiiici i n  
developing countrics. 
Short course antibiotic therapy with 
macrolides 
Risk-benefit of short-course therapy with 
macrolides 
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Due to favorable plidriiiacokinetics, shorter therapeutic regimens are 
now used with some of the newer macrolides. Thcte product\ ,ire 
characterized by rapid and substmtial intraccllul'ir accumulation, 
pxticul'irly in the lysosome~, followed by slow releaw from the cell\. 
so that intracellular concentrations can wrpacr blood c~ncen t r a t~ons  
by several hundred-fold. Among nixrohde\, azithromycin display\ 
the most important intracellular accumulatioii. making possible 
umplified docing. Most m.icrolide-~iisc.eptible respiratory t r x t  
infections can be etiiciently treated by once-a-day doring for 3 day\ 
with azithroinyrin; genital and eye infections causcd by W m y d i ~ i  
iruchonzatis are controlled with a single do\? of the drug. There I\ :I 
trend to extend the concept ufa cingle therapeutic dow in respir.itory 
infections. more p.irticularly in acute utitij media 'nid pharyiigitis, 
with the scinie ton1 dose as in the more conventional t r rmiet i t  (30 
m g i k g  for a child). Compared to the 3-day regimen, the single dosc 
assures the smie  serum hdf-life and AUC, but ni~xiii ium antibiotic 
concentrcitioiis appear earlier (at day 1 versus day 3)  Jnd reach higher 
levels. In theory, this could provide improved efficacy and  11mit the 
risk of resistance selection. The  single dose could l e d  t o  1 INPo 
conipliance if the drug I\ taken in presence of hexh  perwnnel. 
Improved compliance decreases the risk oftherapcutir failure md thc 
cost. Possible inconvenience includes more ride sffectc elwicxted 
with drug concentr&nis, particularly the gastruinte\tinal manifest- 
ations. 
Overview of azithromycin therapy 
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Azithroniycin (AZ) has proven in vitro bacteriologic xtivity a g ~ i ~ i s t  
many important comiiiunity-'isqiilreJ Gran-po\it~ve md <;ran- 
negative pathogens, J\ well J\ the xypical respiratory pclthogen\ I n  
2 8  C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  Vo lume 5 S u p p l e m e n t  3 
addition, its pharniacokinetics distinguish AZ from the traditional 
antibiotics. After the initial rapid absorption, AZ levels in tissues 
remain above the minimum inhibitory concentrations for these 
organisms for up to 8 days. The unique pharniacokinetics of AZ 
enable once-daily administration for only 3 days to provide etfective 
therapy comparable to that achieved with other antiiiiicrobial agents 
given as multiple daily doses for up to 10 days. A meta-analysis of 
randomized, comparative clinical studies comparing AZ with peni- 
cillins, cephalosporins and rnacrolides has demonstrated its 
comparable clinical and bacteriologic efficacy in the treatment of 
adults with community-acquired upper or lower respiratory tract 
infections. By the end of treatment, more than 90% of patients had 
a successful clinical response, and nearly 90% of the bacteria detected 
before treatment were eradicated from the respiratory tract. In clinical 
studies in more than 1500 adults receiving a once-daily, 3-day course 
of therapy, AZ was as well tolerated as comparator agents, with a 
similar incidence of laboratory abnormalities and discontinuations 
from treatment. When used to treat children, AZ has proved equally 
effective and safe. A combination of once-daily dosing, a shorter 
course of therapy compared with first-line agents, and good tolera- 
tion of AZ, all contribute to patient compliance, and may help to 
optimize the treatment of coiiiiiiuiiity-acquired respiratory tract 
infections. 
Single-dose therapy in otitis media 
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Acute otitis media (AOM) is one of the most common infectious 
disease5 of childhood and also one of the most common conditions 
for antimicrobial prescription in pediatrics. Bacterial pathogens are 
isolated from middle-ear fluid in about two-thirds of patients and, in 
most parts of the world, antimicrobial therapy is considered standard 
therapy. The choice of antibiotic is based on antimicrobial spectrum, 
pharmacokinetic properties, safety and cost. Although 10 days is 
currently considered the standard duration of therapy, poor coin- 
pliance and drug-related side effects strongly suggest the need for 
shorter regimens. Single-dose ceftriaxone (CFT) has been approved 
in a number of countries as a therapeutic option. Published studies 
suggest clinical and bacteriologic results similar to those of standard 
10-day therapy against standard agents; however, its use is limited by 
the incidence of gastrointestinal side effects, need for parenteral 
administration and possibility of selection for resistance. Azithro- 
mycin (AZ) is an azalide antibiotic with good in vitro activity against 
middle-ear pathogens, high middle-ear penetration and a prolonged 
half-life. In patients with AOM, a 3-day regimen of A 2  had a similar 
clinical and bacteriologic efficacy rate to 10-day regimens of standard 
agents. A single-blind clinical trial comparing single-dose, oral AZ, 
3-day AZ and single-dose intramuscular CFT, in children with 
AOM, was completed in Costa Rica. O f  a total of 180 clinically 
evaluable patients, clinical cure and bacteriologic eradication was 
observed in 97% of patients in the single-dose AZ group, 98%) in the 
3-day AZ group and 100% in the CFT group (P=NS). Adverse 
events were infrequent in all three groups. These data suggest that 
larger clinical trials with single dose-AZ in pediatric patients are 
warranted. 
Azithromycin in hyperendernic trachoma 
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Trachoma is the world's leading cause of preventable blindness: 600 
million people live in endemic areas, with 6 million blind. To prevent 
blindness, long courses of topical tetracycline are given to children 
or entire communities (mass treatment). Oral antibiotics are more 
effective, but the long courses required are impractical in developing 
countries. Azithroniycin, with a dosing advantage, and good anti- 
chlamydia1 activity, offers an intriguing possibility for trachoma 
control. In a inulticenter trial, we evaluated community-wide 
treatment in trachoma-endemic villages in Egypt, Tanzania and The 
Gambia. Oral azithroniycin, given weekly three times to assure 
coverage, was compared with 6 wceks of daily topical tetracycline. 
Among those with active trachoma, ocular chlamydia1 infection, as 
determined by ligase chain reaction (LCR), was detected in 50%. 
This dropped dramatically post-treatment (up to 90%)) at all sites. 
Infection rates seen after azithroniycin in Egypt and Tanzania were 
lower than after tetracycline; these low rates persisted. In contrast, in 
The Gambia, there was no difference in LCR positivity between 
groups by the 2-month follow-up, possibly due to high rates of 
inward migration of untreated individuals. At all sites, the year-end 
infection rates were significantly lower than at baseline. In practice, 
the benefits of oral azithromycin will be even greater, as compliance 
with topical tetracycline will be much lower than under our research 
conditions. Fewer oral doses are more convenient, less irritating and 
better tolerated than multiple doses of eye ointment. It will certainly 
require treatment of larger areas, and possibly retreatnient, but 
community-wide treatment with azithromyciii inay provide control 
of blinding trachoma. 
[=I Single-dose therapy of sexually transmitted 
diseases 
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Compliance is a major consideration in the management of STDs. 
The development of drugs, such as azithromycin (AZ), with en- 
hanced intracellular penetration and a prolonged half-life, has 
increased the possibility of single-dose therapy. The ideal antibiotic 
for single-dose treatment must be orally active against common 
pathogens, free of significant side effects and economic. AZ is highly 
active in vitro against the intracellular and cell-associated pathogens 
Chlamydia trachumatis, Neisseria gonorrhoeae and Ureaplasmn iirealytitum, 
as well as against Haemophilirs ducreyi. In general, macrolides are not 
reliable for the single-dose therapy of lower genital tract gonorrhoea. 
However, a single 1-g oral dose of AZ is effective, provided that the 
organism is known not to be macrolide resistant. Uncomplicated 
non-gonococcal genital infection is conventionally treated with a 
7-day oral course of either a tetracycline or erythromycin. Neither is 
ideal, owing to gastrointestinal side effects and problems with 
compliance. Several controlled clinical trials have demonstrated that 
a single 1-g oral dose of A 2  is as efficacious as a week's course of 
doxycycline or erythromycin. Chlamydia is reliably eradicated in both 
men and women, and the clinical response rate is around 85% with 
either single-dose A 2  therapy or conventional multidose therapy, in 
both chlamydia1 and non-specific infection. Chancroid is the com- 
monest bacterial cause of genital ulcer disease worldwide. A single 
I-g oral dose of AZ is equivalent to a week's course of erythromycin, 
or a single IM dose of ceftriaxone. Side effects of oral AZ are 
comparatively mild. Pharmacoeconomic studies indicate that savings 
in total episode care should offset the higher basic cost of AZ. 
